This post was originally published on this site
The resurgence of COVID-19 cases due to its Delta variant’s rapid spread is hiking demand for vaccines. The COVID-19 vaccine market is expected to grow at a 7.6% CAGR to $19.50 billion by 2026. Given this backdrop, both MRNA and INO should benefit.
But while INO’s shares lost 26.3% in price over the past nine months, MRNA’s have surged 178.1%. MRNA is also a clear winner with 14.7% price gains versus INO’s 2.7% returns over the past month. But which of these stocks is a better pick now? Let’s find out.
